Search

Your search keyword '"Eagle Pharmaceuticals Inc. -- Intellectual property"' showing total 26 results
Start Over Descriptor "Eagle Pharmaceuticals Inc. -- Intellectual property" Topic united states. food and drug administration
26 results on '"Eagle Pharmaceuticals Inc. -- Intellectual property"'

1. Eagle Pharmaceuticals Granted Patent for PEMFEXY(R)

Subjects
United States. Securities and Exchange Commission, United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Pemetrexed -- Intellectual property, Drug approval, Banking, finance and accounting industries, Business, Pemfexy (Medication) -- Intellectual property
Abstract

WOODCLIFF LAKE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or the 'Company') today announced that the U.S. Patent and Trademark Office has granted the [...]

Published
2023

2. Eagle Pharmaceuticals secures key patent for PEMFEXY in US market

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Pemetrexed -- Intellectual property, Drug approval, Chemistry, Pemfexy (Medication) -- Intellectual property
Abstract

M2 PHARMA-October 24, 2023-Eagle Pharmaceuticals secures key patent for PEMFEXY in US market (C)2023 M2 COMMUNICATIONS US pharmaceutical company Eagle Pharmaceuticals Inc (Nasdaq:EGRX) announced on Tuesday that the US Patent [...]

Published
2023

3. Eagle Pharmaceuticals secures key patent for PEMFEXY in US market

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Pemetrexed -- Intellectual property, Drug approval, Business, Pemfexy (Medication) -- Intellectual property
Abstract

M2 EQUITYBITES-October 24, 2023-Eagle Pharmaceuticals secures key patent for PEMFEXY in US market (C)2023 M2 COMMUNICATIONS http://www.m2.co.uk US pharmaceutical company Eagle Pharmaceuticals Inc (Nasdaq:EGRX) announced on Tuesday that the US [...]

Published
2023

4. Endo International gets Paragraph IV notification on Vasostrict

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Par Pharmaceutical Inc. -- Intellectual property, Generic drugs, Pharmaceutical industry -- Intellectual property, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Endo International plc announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC, have received a Notice Letter dated April 16, 2018 advising that Eagle Pharmaceuticals, Inc. (Eagle) [...]

Published
2018

5. Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA (Updated on 22-08-2018)

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

WOODCLIFF LAKE: Eagle Pharmaceuticals, Inc. has issued the following press release: Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that an additional patent has been issued related [...]

Published
2018

6. Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Patent/copyright issue, Business, Business, international
Abstract

- BENDEKA protected by 16 patents running from 2026 through 2033 - - Fifteen total Orange Book listed patents - WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' [...]

Published
2018

7. Endo Receives Paragraph IV Notification on Vasostrict

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Par Pharmaceutical Inc. -- Intellectual property, Generic drugs, Drug approval, Pharmaceutical industry -- Intellectual property, Business, News, opinion and commentary
Abstract

DUBLIN, April 17, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC, have received a Notice Letter dated [...]

Published
2018

8. Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Business, Business, international, Ryanodex (Medication)
Abstract

-- Bendeka market share of 97% with record royalty revenue of $41.4 million -- -- Revenue grows 67% year-over-year to $63.0 million -- -- New patent related to RYANODEX granted [...]

Published
2017

9. Eagle Pharmaceuticals awarded three new patents in the US for Bendeka

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

Mar 22, 2017 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Eagle Pharmaceuticals Inc (NasdaqGM:EGRX) revealed on Tuesday the receipt of three additional patents protecting Bendeka from the US Patent and [...]

Published
2017

10. New US Patent Issued for Eagle Pharmaceuticals' Bendeka

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Chemistry
Abstract

M2 PHARMA-August 23, 2018-New US Patent Issued for Eagle Pharmaceuticals' Bendeka (C)2018 M2 COMMUNICATIONS - An additional patent has been issued related to Bendeka by the United States Patent and [...]

Published
2018

11. USPTO Grants New Patent for Eagle Pharma's Bendeka

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Chemistry
Abstract

M2 PHARMA-July 9, 2018-USPTO Grants New Patent for Eagle Pharma's Bendeka (C)2018 M2 COMMUNICATIONS - Woodcliff Lake, New Jersey-based specialty pharmaceutical company Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) has been issued [...]

Published
2018

12. Eagle Pharmaceuticals receives new BENDEKA patent

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Chemistry
Abstract

M2 PHARMA-July 4, 2018-Eagle Pharmaceuticals receives new BENDEKA patent (C)2018 M2 COMMUNICATIONS Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has been granted an additional patent for BENDEKA (bendamustine hydrochloride) injection, the pharmaceutical company [...]

Published
2018

13. Eagle Pharmaceuticals receives new BENDEKA patent

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Business
Abstract

M2 EQUITYBITES-July 4, 2018-Eagle Pharmaceuticals receives new BENDEKA patent (C)2018 M2 COMMUNICATIONS http://www.m2.com Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has been granted an additional patent for BENDEKA (bendamustine hydrochloride) injection, the pharmaceutical [...]

Published
2018

14. Eagle Pharmaceuticals awarded new US patent for BENDEKA running through to 2031

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Chemistry
Abstract

M2 PHARMA-July 4, 2018-Eagle Pharmaceuticals awarded new US patent for BENDEKA running through to 2031 (C)2018 M2 COMMUNICATIONS Pharmaceutical company Eagle Pharmaceuticals Inc (Nasdaq:EGRX) revealed on Tuesday the receipt of [...]

Published
2018

15. Eagle Pharmaceuticals awarded new US patent for BENDEKA running through to 2031

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Business
Abstract

M2 EQUITYBITES-July 4, 2018-Eagle Pharmaceuticals awarded new US patent for BENDEKA running through to 2031 (C)2018 M2 COMMUNICATIONS http://www.m2.com Pharmaceutical company Eagle Pharmaceuticals Inc (Nasdaq:EGRX) revealed on Tuesday the receipt [...]

Published
2018

16. Eagle Pharmaceuticals awarded three new patents in the US for Bendeka

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Patent/copyright issue, Chemistry
Abstract

M2 PHARMA-March 22, 2017-Eagle Pharmaceuticals awarded three new patents in the US for Bendeka (C)2017 M2 COMMUNICATIONS Pharmaceutical company Eagle Pharmaceuticals Inc (NasdaqGM:EGRX) revealed on Tuesday the receipt of three [...]

Published
2017

17. Eagle Pharmaceuticals awarded three new patents in the US for Bendeka

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Patent/copyright issue, Business
Abstract

M2 EQUITYBITES-March 22, 2017-Eagle Pharmaceuticals awarded three new patents in the US for Bendeka (C)2017 M2 COMMUNICATIONS http://www.m2.com Pharmaceutical company Eagle Pharmaceuticals Inc (NasdaqGM:EGRX) revealed on Tuesday the receipt of [...]

Published
2017

18. Eagle Pharmaceuticals awarded 11th US patent for Bendeka

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Patent/copyright issue, Chemistry
Abstract

M2 PHARMA-March 1, 2017-Eagle Pharmaceuticals awarded 11th US patent for Bendeka (C)2017 M2 COMMUNICATIONS Pharmaceutical company Eagle Pharmaceuticals Inc (NYSE:EGRX) reported on Tuesday that it has received its 11th US [...]

Published
2017

19. Eagle Pharmaceuticals awarded 11th US patent for Bendeka

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Patent/copyright issue, Business
Abstract

M2 EQUITYBITES-March 1, 2017-Eagle Pharmaceuticals awarded 11th US patent for Bendeka (C)2017 M2 COMMUNICATIONS http://www.m2.com Pharmaceutical company Eagle Pharmaceuticals Inc (NYSE:EGRX) reported on Tuesday that it has received its 11th [...]

Published
2017

20. Eagle Pharmaceuticals Receives New Patent for Bendamustine Rapid Infusion Product

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Teva Pharmaceutical Industries Ltd. -- Intellectual property, Patents, Pharmaceutical industry -- Intellectual property, Antineoplastic agents, Patent/copyright issue, Business, Business, international
Abstract

WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ('Eagle') today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,144,568, which pertains to the [...]

Published
2015

21. New Patent Issued for Eagle Pharmaceuticals' Bendamustine Rapid Infusion Product

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Teva Pharmaceutical Industries Ltd. -- Intellectual property, Patents, Pharmaceutical industry -- Intellectual property, Drug approval, Antineoplastic agents, Patent/copyright issue, Business, Business, international
Abstract

WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ('Eagle' or the 'Company') today announced that the United States Patent and Trademark Office ('USPTO') has granted U.S. Patent No. 9,034,908, which [...]

Published
2015

22. Eagle Pharmaceuticals Announces New Patent for Low-Sodium Bendamustine

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Teva Pharmaceutical Industries Ltd. -- Intellectual property, Patents, Pharmaceutical industry -- Intellectual property, Antineoplastic agents, Patent/copyright issue, Business, Business, international
Abstract

WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ('Eagle' or the 'Company') today announced that the United States Patent and Trademark Office ('USPTO') has granted Patent No. 9,000,021 for the [...]

Published
2015

23. Eagle Pharmaceuticals' Exclusive Licensor Granted U.S. Patent for Dantrolene in the Treatment of Heat Stroke

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Heatstroke, Dantrolene, Central nervous system depressants, Patents, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, Business, Business, international
Abstract

WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. ('Eagle') (NASDAQ:EGRX) announced today that the United States Patent and Trademark Office has granted Patent No. 8,685,460 for the treatment of heat stroke [...]

Published
2014

24. NDA for Eagle Pharmaceuticals' Orphan Drug Ryanodex[R] for the Treatment of Malignant Hyperthermia Accepted by FDA, Priority Review Granted

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Malignant hyperthermia -- Drug therapy, Orphan drugs, Pharmaceutical industry -- Intellectual property, Business, Business, international
Abstract

WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. ('EAGLE') (NASDAQ:EGRX) announced today that the United States Food and Drug Administration has accepted the company's New Drug Application for Ryanodex[R] (dantrolene) and [...]

Published
2014

25. Eagle Pharmaceuticals Receives Tentative Approval for Patented, Ready-to-Dilute Bendamustine Hydrochloride Injection NDA

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Teva Pharmaceutical Industries Ltd. -- Intellectual property, Drug approval, Pharmaceutical industry -- Intellectual property, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

By a News Reporter-Staff News Editor at Pharma Business Week -- Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ('Eagle' or 'the Company') announced that the United States Food and Drug Administration ('FDA') has [...]

Published
2014

26. NDA for Eagle Pharmaceuticals' Orphan Drug Ryanodex[R] for the Treatment of Malignant Hyperthermia Accepted by FDA, Priority Review Granted

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Malignant hyperthermia -- Drug therapy, Orphan drugs, Pharmaceutical industry -- Intellectual property, Government, Political science
Abstract

By a News Reporter-Staff News Editor at Politics & Government Week -- Eagle Pharmaceuticals, Inc. ('EAGLE') (NASDAQ:EGRX) announced that the United States Food and Drug Administration has accepted the company's [...]

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results